as of 11-13-2026 3:19pm EST
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.
| Founded: | 2004 | Country: | Singapore |
| Employees: | N/A | City: | N/A |
| Market Cap: | 998.8M | IPO Year: | 2022 |
| Target Price: | $29.50 | AVG Volume (30 days): | 268.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $0.88 - $17.25 | Next Earning Date: | 08-14-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | 243.83% | Revenue Growth (next year): | -55.54% |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | N/A |
CFO
Avg Cost/Share
$14.25
Shares
5,667
Total Value
$80,754.75
Owned After
147,757
SEC Form 4
CFO
Avg Cost/Share
$13.98
Shares
6,000
Total Value
$83,880.00
Owned After
147,757
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Ji Ping | ANL | Director | Sep 30, 2026 | Sell | $15.99 | 10,000 | $159,900.00 | 126,453 | |
| Ji Ping | ANL | Director | Sep 29, 2026 | Sell | $15.77 | 214 | $3,374.78 | 126,453 | |
| Ye Xiaofeng | ANL | CFO | Aug 26, 2026 | Sell | $14.25 | 5,667 | $80,754.75 | 147,757 | |
| Ye Xiaofeng | ANL | CFO | Aug 24, 2026 | Sell | $13.98 | 6,000 | $83,880.00 | 147,757 |
See how ANL stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "ANL Adlai Nortye Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.